Reta research: A1C improvement, Knee Osteoarthritis, Fatty Liver Disease, Lipids, Kidneys, Sleep Apnea, and more

oldrunnerguy

oldrunnerguy

Explorer
Joined
Feb 2, 2026
Messages
77
Reaction score
37
Location
USA
The newest Phase 3 findings (made public in December 2025 and March 2026) indicate retatrutide has grown well past its reputation as merely a "weight loss drug." Since it acts on 3 separate hormones—GLP-1, GIP, and Glucagon—it functions as a body-wide metabolic "clean-up" mechanism.

Below is a summary of the latest studies covering retatrutide's uses beyond weight: GLP1's are definitely having a moment! Showing great efficacy for those wanting to lose weight, and so much more.

1. Data released on March 19, 2026 demonstrated that retatrutide delivered enormous glycemic control benefits:​#-1-in-results-published-on-march-19-2026-retatrutide-showed-massive-efficacy-in-glycemic-control
  • A1C Reduction: Over 40 weeks, participants experienced an average A1C drop of 1.7% to 2.0% [1.2].
  • Glycemic Reach: A large share of participants achieved glucose levels close to normal, which hints that it could outperform existing dual-agonists for managing blood sugar.
2. Among the most unexpected findings from the December 2025 dataset was how the drug affected chronic pain:​#-2-one-of-the-most-surprising-resu...025-data-was-the-drugs-impact-on-chronic-pain
  • Pain Reduction: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores fell by 75.8% among participants [2.2].
  • Mechanical vs. Inflammatory: Part of this comes from less weight bearing down on the joints, but the drug also brought down hsCRP (an inflammation marker throughout the body) substantially, pointing to a direct anti-inflammatory action within joint tissue itself.
3. For resolving Metabolic Dysfunction-Associated Steatohepatitis (MASH), retatrutide currently holds the "front runner" position:​#-3-retatrutide-is-currently-the-fr...c-dysfunction-associated-steatohepatitis-mash
  • Steatosis Resolution: Phase 2 results indicated that 85-90% of participants reached "normalization" of liver fat (liver fat <5%) by 48 weeks [3.2].
  • Phase 3 Ongoing: The SYNERGY-Outcomes trial is right now assessing whether retatrutide can stop "major adverse liver outcomes" (such as cirrhosis) in high-risk patients [3.1].

    4. Cardiovascular & Kidney Protection
The TRIUMPH-Outcomes trial (updated in March 2026) is specifically studying retatrutide’s ability to prevent heart attacks and kidney failure [5.3]:

  • Blood Pressure: Fresh data reveals an average systolic blood pressure (SBP) decrease of 14.0 mmHg [1.1].
  • Lipid Clearing: It brings down triglycerides and non-HDL cholesterol markedly, possibly providing "primary prevention" against heart disease.
5. Sleep Apnea & Chronic Back Pain​#-5-sleep-apnea-chronic-back-painThe TRIUMPH-1 trial (expected completion mid-2026) is evaluating:

  • Obstructive Sleep Apnea (OSA): Measuring the reduction in the Apnea-Hypopnea Index (AHI) [4.1].
  • Chronic Low Back Pain: Looking at how systemic inflammation reduction and weight loss combine to relieve spinal pressure.
Why it works for so many things: The "Triple Agonist" Effect​#-why-it-works-for-so-many-things-the-triple-agonist-effectWhat sets retatrutide apart is its capacity to activate Glucagon receptors alongside GLP-1 and GIP—this is the "secret sauce" behind these non-weight benefits.

  • GLP-1: Reduces appetite and calms the immune system.
  • GIP: Improves how the body clears lipids and reduces bone resorption.
  • Glucagon: Increases energy expenditure and promotes liver fat oxidation (burning fat directly in the liver).

During my working life, I was a pharmacist for more than 43 years. Way the hell back in the early 90's I remember reading about an exciting new class of drugs showing tremendous potential for a variety of afflictions, but the focus was about diabetics and weight loss. I find this class of drugs fascinating, and their potential to improve health outcomes for mllions and millions of people. 30+ years later and I'm totally nerding out on everything GLP1-related. Reta is incredible, and I'm excited to learn about current research on the quadruple agonist drug NA-931 Bioglutide. (Look it up).
 
Absolutely, Reta has my enthusiasm, and my wish is that once it launches officially, everyone will be able to obtain it without hassle!
 
oldrunnerguy said:

The newest Phase 3 findings (made public in December 2025 and March 2026) indicate retatrutide has grown well past its reputation as merely a "weight loss drug." Since it acts on 3 separate hormones—GLP-1, GIP, and Glucagon—it functions as a body-wide metabolic "clean-up" mechanism.

Below is a summary of the latest studies covering retatrutide's uses beyond weight: GLP1's are definitely having a moment! Showing great efficacy for those wanting to lose weight, and so much more.

1. Data released on March 19, 2026 demonstrated that retatrutide delivered enormous glycemic control benefits:​#-1-in-results-published-on-march-19-2026-retatrutide-showed-massive-efficacy-in-glycemic-control
  • A1C Reduction: Over 40 weeks, participants experienced an average A1C drop of 1.7% to 2.0% [1.2].
  • Glycemic Reach: A large share of participants achieved glucose levels close to normal, which hints that it could outperform existing dual-agonists for managing blood sugar.
2. Among the most unexpected findings from the December 2025 dataset was how the drug affected chronic pain:​#-2-one-of-the-most-surprising-resu...025-data-was-the-drugs-impact-on-chronic-pain
  • Pain Reduction: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores fell by 75.8% among participants [2.2].
  • Mechanical vs. Inflammatory: Part of this comes from less weight bearing down on the joints, but the drug also brought down hsCRP (an inflammation marker throughout the body) substantially, pointing to a direct anti-inflammatory action within joint tissue itself.
3. For resolving Metabolic Dysfunction-Associated Steatohepatitis (MASH), retatrutide currently holds the "front runner" position:​#-3-retatrutide-is-currently-the-fr...c-dysfunction-associated-steatohepatitis-mash
  • Steatosis Resolution: Phase 2 results indicated that 85-90% of participants reached "normalization" of liver fat (liver fat <5%) by 48 weeks [3.2].
  • Phase 3 Ongoing: The SYNERGY-Outcomes trial is right now assessing whether retatrutide can stop "major adverse liver outcomes" (such as cirrhosis) in high-risk patients [3.1].

    4. Cardiovascular & Kidney Protection
The TRIUMPH-Outcomes trial (updated in March 2026) is specifically studying retatrutide’s ability to prevent heart attacks and kidney failure [5.3]:

  • Blood Pressure: Fresh data reveals an average systolic blood pressure (SBP) decrease of 14.0 mmHg [1.1].
  • Lipid Clearing: It brings down triglycerides and non-HDL cholesterol markedly, possibly providing "primary prevention" against heart disease.
5. Sleep Apnea & Chronic Back Pain​#-5-sleep-apnea-chronic-back-painThe TRIUMPH-1 trial (expected completion mid-2026) is evaluating:

  • Obstructive Sleep Apnea (OSA): Measuring the reduction in the Apnea-Hypopnea Index (AHI) [4.1].
  • Chronic Low Back Pain: Looking at how systemic inflammation reduction and weight loss combine to relieve spinal pressure.
Why it works for so many things: The "Triple Agonist" Effect​#-why-it-works-for-so-many-things-the-triple-agonist-effectWhat sets retatrutide apart is its capacity to activate Glucagon receptors alongside GLP-1 and GIP—this is the "secret sauce" behind these non-weight benefits.

  • GLP-1: Reduces appetite and calms the immune system.
  • GIP: Improves how the body clears lipids and reduces bone resorption.
  • Glucagon: Increases energy expenditure and promotes liver fat oxidation (burning fat directly in the liver).

During my working life, I was a pharmacist for more than 43 years. Way the hell back in the early 90's I remember reading about an exciting new class of drugs showing tremendous potential for a variety of afflictions, but the focus was about diabetics and weight loss. I find this class of drugs fascinating, and their potential to improve health outcomes for mllions and millions of people. 30+ years later and I'm totally nerding out on everything GLP1-related. Reta is incredible, and I'm excited to learn about current research on the quadruple agonist drug NA-931 Bioglutide. (Look it up).
Click to expand...
Back in the mid 90's, the first so-called 'miracle' weight loss drug, Redux, hit the market, only to be pulled shortly afterward because it triggered heart valve problems and hypertension. Since you're a pharmacist, you likely recall Redux as well.
 
All the reports I come across regarding Reta are fantastic. Appreciate you posting this. I'm at 4 weeks now and doing well.
 
oldrunnerguy said:


… and I'm excited to learn about current research on the quadruple agonist drug NA-931 Bioglutide. (Look it up).

Click to expand...
Click to expand...
Skip it—Bioglutide is a scam. (Do your own research.)

Eloralintide, though, is what catches my attention.

​#-
 
One more piece I meant to include:

Below is an overview of the most recent findings on retatrutide and mental health, current through March 2026.

1. The "Happiness Signal" in Phase 3#-1-the-happiness-signal-in-phase-3Across the TRIUMPH-4 and TRANSCEND data that have come out in the past several months, the researchers gathered "exit interviews" along with Quality of Life (QoL) measures that extended past what the scale alone captured.

  • Emotional Well-being: A qualitative study covering Phase 2 and 3 participants (released in late 2025) found that people described not merely "less hunger" but feeling "happier," "more self-confident," and having a sense of "emotional regulation" that had been absent for years [5.1].
  • Reduction in "Food Noise": Among the mental benefits, this one gets cited most. Once the endless internal bargaining over food quiets down, patients describe "mental clarity" and a lighter cognitive load—the very load that used to feed anxiety and binge-eating cycles [1.1].
2. The Landmark "42% Reduction" Study (March 2026)#-2-the-landmark-42-reduction-study-march-2026The final peer-reviewed "mental health sub-study" on retatrutide is still pending, but a large study that appeared in The Lancet Psychiatry (March 19, 2026) looked at more than 95,000 people taking GLP-1 class drugs.

  • Psychiatric Stability: According to that study, users were 42% less likely to see their mental illness worsen (hospitalization or sick leave) than during periods off the medication [4.1, 4.4].
  • Broad Spectrum: The effect showed up for depression, anxiety, and in particular substance use disorders (47% reduction). Because retatrutide acts as a "triple agonist," researchers suspect it could be even more potent on this front, given how it engages the brain's reward centers.
3. The Mechanism: Neuroinflammation#-3-the-mechanism-neuroinflammationThis is the route by which retatrutide acts on the brain. It isn't simply "feeling good because you look good."

  • Anti-Inflammatory Action: Retatrutide (and its relatives) pass through the blood-brain barrier and lower neuroinflammation—the glial cell activation recognized as a driver of clinical depression and anhedonia [5.2].
  • Dopamine Tuning: Through modulation of the GLP-1 and GIP receptors in the ventral tegmental area (the reward center), these drugs "level out" the dopamine spikes behind impulsive behaviors (food, alcohol, or even "doom-scrolling") [4.2].
4. The 2026 FDA Safety Correction#-4-the-2026-fda-safety-correctionImportant for your "correct way" of approaching this: in January 2026 the FDA announced it is seeking removal of the suicidal ideation warnings from these medications [1.1]. Having reviewed data on more than 100,000 patients, the agency found no increased risk of serious psychiatric side effects, effectively lifting the "dark cloud" that had hung over the class for years.
 
Sadly that summary carries several real scientific errors. The one that jumped out at me straight away was the blood brain barrier claim, that retatrutide and other GLP's get across it. They are simply too big for that; they do reach the brain, but mostly via regions the BBB leaves less guarded, plus knock-on effects from vagal nerve signalling and shifts in hormonal signalling. It would be genuinely interesting to know whether any small molecule multiagonists manage to cross it, and what that would do to the brain — especially for staving off cognitive decline as we age — given how much these drugs achieve when they only touch a fraction of the brain.

Most of the remaining problems come down to overstated effects being framed as far more certain than today's evidence allows. That covers MASH, pain and psychiatric outcomes. Lipids and blood pressure genuinely do improve, and protection against cardiovascular disease and renal function will probably be demonstrated eventually, but that has been shown for tirzepatide and semaglutide rather than for reta so far. Reta does cut liver fat, yet an impact on fibrosis has not been demonstrated, and stopping or reversing fibrosis is what actually counts. It may well be proven one day, but it has not been done yet.

This looks like the classic case of an AI wanting a tidy narrative, so effects get inflated and a few facts come out wrong. Prompting it or using research /scholar mode cuts the problem down .
 
lessthanhalf said:

Sadly that summary carries several real scientific errors. The one that jumped out at me straight away was the blood brain barrier claim, that retatrutide and other GLP's get across it. They are simply too big for that; they do reach the brain, but mostly via regions the BBB leaves less guarded, plus knock-on effects from vagal nerve signalling and shifts in hormonal signalling. It would be genuinely interesting to know whether any small molecule multiagonists manage to cross it, and what that would do to the brain — especially for staving off cognitive decline as we age — given how much these drugs achieve when they only touch a fraction of the brain.

Most of the remaining problems come down to overstated effects being framed as far more certain than today's evidence allows. That covers MASH, pain and psychiatric outcomes. Lipids and blood pressure genuinely do improve, and protection against cardiovascular disease and renal function will probably be demonstrated eventually, but that has been shown for tirzepatide and semaglutide rather than for reta so far. Reta does cut liver fat, yet an impact on fibrosis has not been demonstrated, and stopping or reversing fibrosis is what actually counts. It may well be proven one day, but it has not been done yet.

This looks like the classic case of an AI wanting a tidy narrative, so effects get inflated and a few facts come out wrong. Prompting it or using research /scholar mode cuts the problem down .
Click to expand...

Seeing a post this grounded, this sensible, this connected to real life is exactly why I get excited whenever your name shows up in a thread. I just wanted to express my appreciation for what you bring here.
 
CHELMON01 said:

Is there any mention of the dosage those individuals received?
Click to expand...

oldrunnerguy said:


The latest Phase 3 data (released in December 2025 and March 2026) shows that retatrutide is moving far beyond just being a "weight loss drug." Because it targets three different hormones—GLP-1, GIP, and Glucagon—it acts as a systemic metabolic "clean-up" tool.

Here is the breakdown of the most recent research on retatrutide’s non-weight-related uses: GLP1's are definitely having a moment! Showing great efficacy for those wanting to lose weight, and so much more.

1. In results published on March 19, 2026, retatrutide showed massive efficacy in glycemic control:​
  • A1C Reduction: Participants saw an average A1C reduction of 1.7% to 2.0% over 40 weeks [1.2].
  • Glycemic Reach: Many participants reached "near-normal" glucose levels, suggesting it may be more potent for blood sugar control than current dual-agonists.
2. One of the most surprising results from the December 2025 data was the drug’s impact on chronic pain:​
  • Pain Reduction: Participants saw a 75.8% reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores [2.2].
  • Mechanical vs. Inflammatory: While some of this is due to taking weight off the joints, the drug also significantly lowered hsCRP (a marker of systemic inflammation), suggesting a direct anti-inflammatory effect on the joint tissue itself.
3. Retatrutide is currently the "front runner" for resolving Metabolic Dysfunction-Associated Steatohepatitis (MASH):​
  • Steatosis Resolution: Phase 2 data showed that 85-90% of participants achieved "normalization" of liver fat (liver fat <5%) within 48 weeks [3.2].
  • Phase 3 Ongoing: The SYNERGY-Outcomes trial is currently evaluating whether retatrutide can prevent "major adverse liver outcomes" (like cirrhosis) in high-risk patients [3.1].

    4. Cardiovascular & Kidney Protection
The TRIUMPH-Outcomes trial (updated in March 2026) is specifically studying retatrutide’s ability to prevent heart attacks and kidney failure [5.3]:

  • Blood Pressure: Recent data shows an average systolic blood pressure (SBP) drop of 14.0 mmHg [1.1].
  • Lipid Clearing: It significantly lowers triglycerides and non-HDL cholesterol, potentially offering "primary prevention" for heart disease.
5. Sleep Apnea & Chronic Back Pain​The TRIUMPH-1 trial (expected completion mid-2026) is evaluating:

  • Obstructive Sleep Apnea (OSA): Measuring the reduction in the Apnea-Hypopnea Index (AHI) [4.1].
  • Chronic Low Back Pain: Looking at how systemic inflammation reduction and weight loss combine to relieve spinal pressure.
Why it works for so many things: The "Triple Agonist" Effect​Retatrutide’s unique ability to hit Glucagon receptors in addition to GLP-1 and GIP is the "secret sauce" for these non-weight benefits.

  • GLP-1: Reduces appetite and calms the immune system.
  • GIP: Improves how the body clears lipids and reduces bone resorption.
  • Glucagon: Increases energy expenditure and promotes liver fat oxidation (burning fat directly in the liver).

During my working life, I was a pharmacist for more than 43 years. Way the hell back in the early 90's I remember reading about an exciting new class of drugs showing tremendous potential for a variety of afflictions, but the focus was about diabetics and weight loss. I find this class of drugs fascinating, and their potential to improve health outcomes for mllions and millions of people. 30+ years later and I'm totally nerding out on everything GLP1-related. Reta is incredible, and I'm excited to learn about current research on the quadruple agonist drug NA-931 Bioglutide. (Look it up).

Click to expand...
Click to expand...
Which of these outcomes stem purely from losing weight, and which come from reta acting directly?
 
On Utube I came across a trial where calories stayed equal for everyone. It looks like some regrowth happened, and before this people thought that could not occur. Similar accounts exist for every GLP1, even Liraglutide, which was new to me. I believe I also saw one that was specifically about Rettrutide. Still, the dose is what worries me. Right now I use 1 or 2 mg per week. That is a different situation from titrating all the way to 12mg.
 
Every one of those improvements has shown up for me. I was dealing with all of those conditions, and Reta has resolved them. My lab results are in a separate post. At the end of Sept I'm scheduled for a liver ultrasound. Since the AST and ALT came back fine, the picture ought to look considerably improved at this point. The doctors have earlier scans on file for comparison. Fatty Liver was something I was diagnosed with.
 
Back
Top